Jazz Pharmaceuticals PLC (JAZZ)

147.89
3.30 2.20
NASDAQ : Health Care
Prev Close 151.18
Open 150.00
Day Low/High 148.35 / 150.55
52 Wk Low/High 108.50 / 194.73
Volume 191.69K
Avg Volume 442.70K
Exchange NASDAQ
Shares Outstanding 60.06M
Market Cap 9.17B
EPS 6.60
P/E Ratio 23.52
Div & Yield N.A. (N.A)

Latest News

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

The firm received a "refusal to file letter" from the FDA regarding the new drug application for Inbrija, a potential treatment for Parkinson's disease.

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Strengthens Jazz hematology/oncology portfolio with options for innovative development candidates IMGN779 and IMGN632

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and ImmunoGen, Inc. (Nasdaq: IMGN) today announced that the companies have entered into a collaboration and option agreement granting Jazz Pharmaceuticals exclusive, worldwide rights...

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.

Jazz Pharmaceuticals Announces Positive Results From The Phase 3 TONES 2 Study Of JZP-110 In Narcolepsy Patients With Excessive Sleepiness

Abstract Accepted for Presentation at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017

Jazz Pharmaceuticals Announces Positive Results From The Phase 2/3 EXPRESS Study Of Xyrem In Pediatric Patients With Narcolepsy With Cataplexy

Abstract Accepted for Oral Presentation at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers

Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.

Jazz Pharmaceuticals Reaches Settlement With Hikma Pharmaceuticals Related To Xyrem Patent Litigation

Hikma Granted Right to Sell Authorized Generic of Xyrem in 2023

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, CAA, JAZZ, LFL, MTH, SUM, WYNN Downgrades: REV, TROW, WAGE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Jazz Pharmaceuticals Announces Positive Results From The Phase 3 TONES 3 And TONES 4 Studies Of JZP-110 In Patients With Obstructive Sleep Apnea

Abstracts Accepted for Presentation at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in premarket trading Friday.

How Investors Can Play the Trump Card: Cramer's 'Mad Money' Recap (Monday 1/23/17)

How Investors Can Play the Trump Card: Cramer's 'Mad Money' Recap (Monday 1/23/17)

Jim Cramer looks for domestic stocks he thinks will benefit from lower taxes and deregulation in the Trump era.

Fitbit Is Out, Xilinx Is In: 'Mad Money' Lightning Round

Fitbit Is Out, Xilinx Is In: 'Mad Money' Lightning Round

Jim Cramer says the future doesn't look healthy for Fitbit, but he's bullish on Xilinx and T-Mobile.

TheStreet Quant Rating: B (Buy)